Drug Trial Radar · NCT07802704
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
684
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Dec 5, 2029
Study completion Dec 5, 2029
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate how well risvutatug rezetecan (Ris-Rez) works in treating prostate cancer compared to best supportive/standard of care (BSC) which may include a hormone therapy with an androgen receptor pathway inhibitors (ARPI), by checking whether it makes cancers smaller or disappear completely, if it helps participants live longer, and/or feel better. The study is also assessing whether Ris-Rez is safe and tolerated well by participants and aims to provide a better understanding of the side effects of the drug.
Conditions
- Neoplasms, Prostate
Interventions
Risvutatug rezetecan (Ris-Rez)Biological
Risvutatug rezetecan (Ris-Rez) will be administered.
EnzalutamideDrug
Enzalutamide will be administered.
AbirateroneDrug
Abiraterone will be administered.
PrednisoneDrug
Prednisone will be administered along with Abiraterone.
PrednisoloneDrug
Prednisolone will be administered along with Abiraterone.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic Progression-Free Survival (rPFS) per PCWG3 by BICRTime frame: Up to approximately 169 weeks
- Overall Survival (OS)Time frame: Up to approximately 169 weeks
Locations
6 sites in 4 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Auchenflower, Queensland, Australia · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
GSK Investigational Site
Tottori, Japan · Recruiting
GSK Investigational Site
Gyeonggi-do, South Korea · Recruiting
GSK Investigational Site
Seoul, Seoul Teugbyeolsi, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.